000270311 001__ 270311
000270311 005__ 20250127091753.0
000270311 0247_ $$2doi$$a10.1002/alz.13818
000270311 0247_ $$2pmid$$apmid:38666355
000270311 0247_ $$2pmc$$apmc:PMC11180868
000270311 0247_ $$2ISSN$$a1552-5260
000270311 0247_ $$2ISSN$$a1552-5279
000270311 0247_ $$2altmetric$$aaltmetric:163204413
000270311 037__ $$aDZNE-2024-00783
000270311 041__ $$aEnglish
000270311 082__ $$a610
000270311 1001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b0$$eFirst author
000270311 245__ $$aα-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.
000270311 260__ $$aHoboken, NJ$$bWiley$$c2024
000270311 3367_ $$2DRIVER$$aarticle
000270311 3367_ $$2DataCite$$aOutput Types/Journal article
000270311 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1718718238_13422
000270311 3367_ $$2BibTeX$$aARTICLE
000270311 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000270311 3367_ $$00$$2EndNote$$aJournal Article
000270311 520__ $$aAmyloid beta and tau pathology are the hallmarks of sporadic Alzheimer's disease (AD) and autosomal dominant AD (ADAD). However, Lewy body pathology (LBP) is found in ≈ 50% of AD and ADAD brains.Using an α-synuclein seed amplification assay (SAA) in cerebrospinal fluid (CSF) from asymptomatic (n = 26) and symptomatic (n = 27) ADAD mutation carriers, including 12 with known neuropathology, we investigated the timing of occurrence and prevalence of SAA positive reactivity in ADAD in vivo.No asymptomatic participant and only 11% (3/27) of the symptomatic patients tested SAA positive. Neuropathology revealed LBP in 10/12 cases, primarily affecting the amygdala or the olfactory areas. In the latter group, only the individual with diffuse LBP reaching the neocortex showed α-synuclein seeding activity in CSF in vivo.Results suggest that in ADAD LBP occurs later than AD pathology and often as amygdala- or olfactory-predominant LBP, for which CSF α-synuclein SAA has low sensitivity.Cerebrospinal fluid (CSF) real-time quaking-induced conversion (RT-QuIC) detects misfolded α-synuclein in ≈ 10% of symptomatic autosomal dominant Alzheimer's disease (ADAD) patients. CSF RT-QuIC does not detect α-synuclein seeding activity in asymptomatic mutation carriers. Lewy body pathology (LBP) in ADAD mainly occurs as olfactory only or amygdala-predominant variants. LBP develops late in the disease course in ADAD. CSF α-synuclein RT-QuIC has low sensitivity for focal, low-burden LBP.
000270311 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000270311 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000270311 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000270311 650_7 $$2Other$$aalpha‐synuclein seed amplification assay
000270311 650_7 $$2Other$$aDominantly Inherited Alzheimer Network
000270311 650_7 $$2Other$$aLewy body pathology
000270311 650_7 $$2Other$$aalpha‐synuclein seed amplification assay
000270311 650_7 $$2Other$$areal‐time quaking‐induced conversion
000270311 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000270311 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000270311 650_7 $$2Other$$areal‐time quaking‐induced conversion
000270311 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000270311 650_2 $$2MeSH$$aHumans
000270311 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000270311 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000270311 650_2 $$2MeSH$$aAlzheimer Disease: cerebrospinal fluid
000270311 650_2 $$2MeSH$$aalpha-Synuclein: cerebrospinal fluid
000270311 650_2 $$2MeSH$$aalpha-Synuclein: genetics
000270311 650_2 $$2MeSH$$aFemale
000270311 650_2 $$2MeSH$$aMale
000270311 650_2 $$2MeSH$$aMiddle Aged
000270311 650_2 $$2MeSH$$aLewy Bodies: pathology
000270311 650_2 $$2MeSH$$aAged
000270311 650_2 $$2MeSH$$aMutation
000270311 650_2 $$2MeSH$$aBrain: pathology
000270311 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000270311 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000270311 650_2 $$2MeSH$$aDisease Progression
000270311 693__ $$0EXP:(DE-2719)DIAN-20090101$$5EXP:(DE-2719)DIAN-20090101$$eLongitudinal Study on Dominantly Inherited Alzheimer's Disease$$x0
000270311 7001_ $$aBaiardi, Simone$$b1
000270311 7001_ $$aQuadalti, Corinne$$b2
000270311 7001_ $$aRossi, Marcello$$b3
000270311 7001_ $$aMammana, Angela$$b4
000270311 7001_ $$0P:(DE-2719)2811820$$aVöglein, Jonathan$$b5$$udzne
000270311 7001_ $$0P:(DE-2719)9002620$$aBernhardt, Alexander$$b6$$udzne
000270311 7001_ $$aPerrin, Richard J$$b7
000270311 7001_ $$0P:(DE-2719)2000010$$aJucker, Mathias$$b8$$udzne
000270311 7001_ $$0P:(DE-2719)2811828$$aPreische, Oliver$$b9$$udzne
000270311 7001_ $$0P:(DE-2719)2814244$$aHofmann, Anna$$b10$$udzne
000270311 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b11$$udzne
000270311 7001_ $$aCairns, Nigel J$$b12
000270311 7001_ $$aFranklin, Erin E$$b13
000270311 7001_ $$aChrem, Patricio$$b14
000270311 7001_ $$aCruchaga, Carlos$$b15
000270311 7001_ $$aBerman, Sarah B$$b16
000270311 7001_ $$aChhatwal, Jasmeer P$$b17
000270311 7001_ $$aDaniels, Alisha$$b18
000270311 7001_ $$aDay, Gregory S$$b19
000270311 7001_ $$aRyan, Natalie S$$b20
000270311 7001_ $$aGoate, Alison M$$b21
000270311 7001_ $$aGordon, Brian A$$b22
000270311 7001_ $$aHuey, Edward D$$b23
000270311 7001_ $$aIbanez, Laura$$b24
000270311 7001_ $$aKarch, Celeste M$$b25
000270311 7001_ $$0P:(DE-HGF)0$$aLee, Jae-Hong$$b26
000270311 7001_ $$aLlibre-Guerra, Jorge$$b27
000270311 7001_ $$aLopera, Francisco$$b28
000270311 7001_ $$aMasters, Colin L$$b29
000270311 7001_ $$aMorris, John C$$b30
000270311 7001_ $$aNoble, James M$$b31
000270311 7001_ $$aRenton, Alan E$$b32
000270311 7001_ $$aRoh, Jee Hoon$$b33
000270311 7001_ $$aFrosch, Matthew P$$b34
000270311 7001_ $$aKeene, C Dirk$$b35
000270311 7001_ $$aMcLean, Catriona$$b36
000270311 7001_ $$aSanchez-Valle, Raquel$$b37
000270311 7001_ $$aSchofield, Peter R$$b38
000270311 7001_ $$aSupnet-Bell, Charlene$$b39
000270311 7001_ $$aXiong, Chengjie$$b40
000270311 7001_ $$aGiese, Armin$$b41
000270311 7001_ $$aHansson, Oskar$$b42
000270311 7001_ $$aBateman, Randall J$$b43
000270311 7001_ $$aMcDade, Eric$$b44
000270311 7001_ $$aNetwork, Dominantly Inherited Alzheimer$$b45$$eCollaboration Author
000270311 7001_ $$00000-0002-9444-9524$$aParchi, Piero$$b46
000270311 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.13818$$gVol. 20, no. 6, p. 4351 - 4365$$n6$$p4351 - 4365$$tAlzheimer's and dementia$$v20$$x1552-5260$$y2024
000270311 8564_ $$uhttps://pub.dzne.de/record/270311/files/DZNE-2024-00783.pdf$$yOpenAccess
000270311 8564_ $$uhttps://pub.dzne.de/record/270311/files/DZNE-2024-00783.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000270311 909CO $$ooai:pub.dzne.de:270311$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000270311 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000270311 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811820$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000270311 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002620$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000270311 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000010$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000270311 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811828$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000270311 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814244$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000270311 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000270311 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000270311 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000270311 9141_ $$y2024
000270311 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000270311 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000270311 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000270311 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000270311 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-25$$wger
000270311 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000270311 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000270311 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000270311 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000270311 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000270311 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000270311 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000270311 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000270311 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x1
000270311 980__ $$ajournal
000270311 980__ $$aVDB
000270311 980__ $$aUNRESTRICTED
000270311 980__ $$aI:(DE-2719)1111015
000270311 980__ $$aI:(DE-2719)1210001
000270311 9801_ $$aFullTexts